All About

HEOR | RWE

At KMK, our over 20 years of expertise enable us to develop your product's value story to reveal business insights for more educated decision-making including the use of real-world studies to showcase your drug’s efficacy and its value in the marketplace.

Get a detailed vision of our HEOR, Real World Data  & Real-World Evidence ​solutions and offerings. 

Case Studies

White Paper

Webinars

Publications

KMK’s Latest Case Studies

Case Studies

Discover

IN-DEPTH
ANALYSIS​

Explore KMK’s customer success stories and discover how our expert team helps clients identify their problems, come up with the best solution, and deliver results. ​

Sorry, we couldn't find any posts. Please try a different search.

KMK’s Latest

White Papers

Our

LATEST
RESEARCH

KMK’s best thinking & expertise will guide you to better understand complex business problems and determine the best way forward for your business.

KMK’s Latest

Learn From

EXPERTS

Watch KMK’s expert opinions and discussions on the latest industry trends to gain deeper insight and learn the best way to plan feasible commercial strategies for your business.

Sorry, we couldn't find any posts. Please try a different search.

KMK’s Latest

Gain

INSIGHTFUL
KNOWLEDGE

Read the latest publications by KMK leaders and experts and learn more about the dynamics of the pharmaceutical industry to identify new opportunities and maintain a competitive edge.

Migraine

Neurology: Clinical Practice

Unmet Need in the Market Economic Burden Increased with Number of Treatment Failures in Migraine Patients – A Retrospective Claims Database Analysis in the United States

KMK Participants : Lujia Zhou

Psoriatic arthritis

Springer-Drugs-Real World Outcomes

Association Between Treatment Patterns and Healthcare Utilization Healthcare Cost and Utilization Associated With Biologic Treatment Patterns Among Patients With Psoriatic Arthritis: Analyses From a Large US Claims Database

KMK Participants : Piao OW, Zheng JZ

Rheumatoid Arthritis

Rheumatology and Therapy

Understanding Real-world Patient Profiles & Identifying Primary Product Benefactor Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis

KMK Participant : Fahim M

lymphoma

Real-World Treatment Patterns

Real-World Treatment Patterns among Patients with Mycosis Fungoides and Sézary Syndrome in the United States between 2018 and 2020

KMK Participant : Huanxue Z.

Multiple Sclerosis

International Journal of MS Care

Impact of switching to fingolimod versus injectable disease-modifying therapy cycling on risk of multiple sclerosis-related relapses: A retrospective analysis

KMK Participants : Huanxue Zhou, Olivia Wenxian Piao 

Ankylosing spondylitis

Journal of Managed Care Specialty Pharmacy

Healthcare Utilization and Cost Associated With Switching Biologics Within the First Year of Biologic Treatment Initiation Among Patients With Ankylosing Spondylitis

KMK Participants : Piao OW, Zheng JZ

Multiple Sclerosis

Advances in Therapy

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis

KMK Participants : Huanxue Zhou

Psoriasis

Clinicoeconomics And Outcomes Research

Group-Based Trajectory Modeling To Assess Adherence To Biologics Among Patients With Psoriasis

KMK Participants : Huanxue Zhou

Migraine

The Journal of Headache and Pain

Real-world Product Value Demonstration Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study

KMK Participants :Shen Y, Zhou L

Multiple Sclerosis

International Journal of MS Care

Utilization and Treatment Patterns of Disease-Modifying Therapy Among Pediatric Patients With Multiple Sclerosis in the United States

KMK Participants : Mengru Wang

Follicular Lymphoma

JHEOR

Treatment patterns and health care costs in commercially insured patients with follicular lymphoma

KMK Participants : Chen G

Psoriasis

Journal Of Managed Care & Specialty Pharmacy

Economic Impact Of Above-Label Dosing With Etanercept, Adalimumab, Or Ustekinumab In Patients With Psoriasis

KMK Participants : Huanxue Zhou